ASX: CHM - Chimeric completes milestones in cell therapy trial for cancer patients

Wednesday, May 12, 2021 at 3:33:15 PM GMT+10:00

Chimeric Therapeutics, ASX:CHM, is a clinical stage cell therapy company focused on bringing cell therapy to patients with cancer. Today, Boardroom.Media reporter Velvet-Belle Templeman is joined by Jennifer Chow, Chief Operating Officer of Chimeric Therapeutics to brief the market on their Chlorotoxin CAR T trial and clinical developments.

Leave a Comment

Your email address will not be published
you may like image
ASX: CHM - Chimeric comple...

ASX: CHM - Chimeric comple...

ASX: RAC - Race placement ...

ASX: RAC - Race placement ...

Mesoblast Corporate Update

Mesoblast Corporate Update

AnteoTech - EuGeni Launch

AnteoTech - EuGeni Launch

World Wide Webcasts

World Wide Webcasts

Mesoblast Corporate Update

Mesoblast Corporate Update

WEBCAST Calendar

  • 10 May

    01:00

    First Quarter 2021 Conference Call May 7, 2021

    EOG RESOURCES
  • 10 May

    02:00

    Shot on iPhone 12 — Everyday Experiments: Full Bloom | Apple May 7, 2021

    APPLE INC
  • 10 May

    02:00

    Magmatic Resources - RIU Sydney Resources Round-up 6th May 2021

    MAGMATIC RESOURCES LIMITED
  • 10 May

    02:00

    Mike Young Vimy Resources (ASX:VMY) RIU 2021 Sydney Resources Roundup

    VIMY RESOURCES LIMITED
  • 10 May

    02:00

    Neometals staying focused on the global EV battery recycling opportunity 7th May 2021

    NEOMETALS LTD